Certara Reports Q1 Net Loss, Misses Adjusted EPS, and Confirms Substantial Loss on Divestiture

summarizeSummary

Certara reported a Q1 net loss and missed adjusted EPS, alongside a significant expected loss from a business divestiture, despite ongoing share repurchases.

check_boxKey Events

• Swing to Net Loss in Q1 2026

  The company reported a net loss of $8.8 million for Q1 2026, a significant decline from a net income of $4.7 million in Q1 2025. Basic and diluted EPS also turned negative at $(0.06) per share.

• Adjusted EPS Misses Estimates

  Adjusted diluted EPS for Q1 2026 was $0.09, missing the IBES estimate of $0.11, indicating underperformance relative to analyst expectations.

• Substantial Loss Expected from Divestiture

  The company completed the sale of its Regulatory and Medical Writing business on May 8, 2026, for up to $135 million in cash and earn-outs. Certara expects to recognize a substantial loss on this transaction, ranging from approximately $28.9 million to $53.7 million.

• Decreased Operating Cash Flow

  Net cash provided by operating activities decreased to $11.7 million in Q1 2026 from $17.4 million in Q1 2025, reflecting lower cash-adjusted net income and increased cash used for prepaid expenses.

auto_awesomeAnalysis

Certara's first-quarter results show a significant financial downturn, with the company swinging to a net loss and missing adjusted EPS estimates. This negative performance is compounded by a substantial expected loss from the recently completed divestiture of its Regulatory and Medical Writing business. While the company continued its share repurchase program, the overall financial picture indicates challenges, especially with declining operating cash flow. The stock is currently trading near its 52-week low, and these results provide further context for investor concerns.